Last reviewed · How we verify

NCT06327659

Efficacy of Using 50 ml Syringe Manual Thrombectomy Catheter in Primary PCI With Heavy Thrombus Burden

Status unknown Phase 3 Last updated 26 March 2024
What this trial tests

Phase 3 trial testing 30 mL syringe manual thrombectomy catheter in STEMI - ST Elevation Myocardial Infarction in 88 participants. Status unknown.

Timeline
1 April 2024
Primary endpoint
1 January 2025
1 January 2025

Quick facts

Lead sponsorHelwan University
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment88
Start date1 April 2024
Primary completion1 January 2025
Estimated completion1 January 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Helwan University

Who can join

18 and older, any sex, with STEMI - ST Elevation Myocardial Infarction or Thrombosis Cardiac. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In high thrombus burden subgroup of Acute STEMI, manual aspiration thrombectomy was associated with reduced cardiovascular death but increased stroke or transient ischemic attack. The role of aspiration thrombectomy is still a matter of active debate. Manual aspiration suffers from decreasing aspiration force as the syringe fills with fluid and requires the operator to exchange syringes during the procedure to maintain suction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for STEMI - ST Elevation Myocardial Infarction

Currently open trials in the same condition.

Other Helwan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06327659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing